Page last updated: 2024-12-05

bis(2-chloroethoxy)methane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(2-chloroethoxy)methane: a solvent used in polysulfide elastomer production; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8147
CHEMBL ID1893366
SCHEMBL ID113161
MeSH IDM0480033

Synonyms (69)

Synonym
di-2-chloroethyl formal
wln: g2o1o2g
nsc5212
111-91-1
dichloroethylformal
ethane,1'-[methylenebis(oxy)]bis[2-chloro-
bis(.beta.-chloroethyl) formal
bis(2-chloroethoxy)methane
formaldehyde bis(2-chloroethyl) acetal
methane, bis(2-chloroethoxy)-
ethane,1'-[methylenebis(oxy)]bis(2-chloro-
2,2-dichloroethylformal
dichloroethyl formal
nsc-5212
formaldehyde bis(.beta.-chloroethyl) acetal
bis(2-chloroethyl) formal
di(2-chloroethyl)formal
1,1'-[methylenebis(oxy)]bis(2-chloroethane)
bis(2-chloroethoxy)-methane
bis(beta-chloroethyl) formal
dichloromethoxy ethane
2,2-dichloroethyl formal
formaldehyde bis(beta-chloroethyl) acetal
bis(beta-chloroethyl)formal
dichlorodiethyl formal
nsc 5212
rcra waste number u024
einecs 203-920-2
ai3-01455
bis(2-chloroethyl)formal
dichlorodiethyl methylal
brn 1698909
ethane, 1,1'-(methylenebis(oxy))bis(2-chloro-
hsdb 1333
rcra waste no. u024
ethane, 1,1'-[methylenebis(oxy)]bis[2-chloro-
NCGC00091442-01
smr000568470
MLS001065594
1-chloro-2-(2-chloroethoxymethoxy)ethane
NCGC00091442-02
AKOS006275640
HMS3039L16
cas-111-91-1
dtxsid4023917 ,
NCGC00257838-01
dtxcid203917
tox21_200284
unii-5288kk0810
ec 203-920-2
4-01-00-03028 (beilstein handbook reference)
5288kk0810 ,
FT-0631632
SCHEMBL113161
2,2-dichloroethyl formal [hsdb]
bis(.beta.-chloroethyl)formal
di(2-chloroethoxy)methane
1,7-dichloro-3,5-dioxaheptane
CHEMBL1893366
1-chloro-2-[(2-chloroethoxy)methoxy]ethane #
NLXGURFLBLRZRO-UHFFFAOYSA-N
W-109063
93966-78-0
1-chloro-2-[(2-chloroethoxy)methoxy]ethane, aldrichcpr
1-chloro-2-[(2-chloroethoxy)methoxy]ethane
bis-(2-chloroethoxy)methane 100 microg/ml in cyclohexane
bis(2-chloroethoxy)-d8-methane
bis-(2-chloroethoxy)methane
Q27260978

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Bioavailability following dermal application was low but was higher in rats than in mice with females of both species showing higher bioavailability than males."( Toxicokinetics of bis(2-chloroethoxy)methane following intravenous administration and dermal application in male and female F344/N rats and B6C3F1 mice.
Cristy, T; Dunnick, JK; Godfrey-Robinson, VD; Graves, SW; Hong, SP; Johnson, JD; Smith, CS; Waidyanatha, S, 2011
)
0.7

Dosage Studied

ExcerptRelevanceReference
" Heart toxicity occurred after 2 days of dosing in all 3 regions of the heart (atrium, ventricle, interventricular septum) and was characterized by myofiber vacuolation, necrosis, mononuclear-cell infiltration, and atrial thrombosis."( Critical pathways in heart function: bis(2-chloroethoxy)methane-induced heart gene transcript change in F344 rats.
Blackshear, P; Cunningham, M; Dunnick, J; Kissling, G; Nyska, A; Parker, J, 2006
)
0.61
" These results demonstrate that subtoxic dosage of a cardiotoxic agent may cause occult cardiotoxicity, reflected by impaired response to ischemia."( Occult cardiotoxicity: subtoxic dosage of Bis(2-chloroethoxy)methane impairs cardiac response to simulated ischemic injury.
Borman, JB; Dunnick, J; Golomb, E; Houminer, E; Kissling, G; Nyska, A; Schneider, A; Schwalb, H, 2007
)
0.6
" Mean body weights of dosed rats were similar to those of the vehicle control groups."( Toxicology and carcinogenesis studies of bis(2-chloroethoxy)methane (CAS No. 111-91-1) in F344/N rats and B6C3F1 mice (dermal studies).
, 2011
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency75.48090.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency24.09020.000221.22318,912.5098AID743035
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency58.85980.003041.611522,387.1992AID1159552; AID1159555
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.27030.001019.414170.9645AID743191
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (60.00)29.6817
2010's5 (33.33)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.77 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]